PepGen Inc.’s Promising Advances in DMD and DM1 Programs Justify Buy Rating

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on PepGen Inc. (PEPG – Research Report). The associated price target remains the same with $20.00.

Joseph Schwartz has given his Buy rating due to a combination of factors related to PepGen Inc.’s progress in their Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company has shown a proactive approach in addressing previous challenges in their DMD program, particularly in terms of safety and communication, which has been reassuring to investors. They are optimistic about the potential to achieve higher dystrophin levels, which could enhance the risk/benefit profile of their treatment.
In the DM1 program, PepGen has demonstrated promising results with their innovative CUG blocking approach, which has shown better-than-expected efficacy and a cleaner safety profile compared to competitors. The improvements in splicing correction and early indicators in functional tests suggest a strong potential for success. These positive developments in both programs underpin Schwartz’s confidence in the company’s future performance, justifying the Buy rating.

In another report released on May 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.

Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PEPG in relation to earlier this year.